-
1.发明授权Reduction in vivo of the inappropriate levels of endogenous and environmental-derived compounds by sustained-release inhibitors of .beta.- g 失效通过β-葡萄糖醛酸酶的缓释抑制剂减少内源和环境衍生化合物的不适当水平的体内
公开(公告)号：US4845123A
公开(公告)日：1989-07-04
申请号：US762339
申请日：1985-08-05
IPC分类号： A61K31/19 , A61K31/365
CPC分类号： A61K31/19 , A61K31/365
摘要： A method for the reduction in vivo of the inappropriate levels of endogenous and environmental-derived compounds by inhibiting the activity of .beta.-glucuronidase in a mammal which comprises the administration to the mammal of an effective amount of a water insoluble, or sparingly soluble, sustained release precursor of glucarolactone or its analog is disclosed. The sustained release precursor of glucarolactone compound is selected from the group consisting of D-glucaric acid, D-galactaric acid, and L-idaric acid or derivatives or analogs. An orally administrable preparation of the sustained release precursor of glucarolactone compound is provided in the form of a capsule tablet, such that the glucarolactone or its analog is slowly released in the stomach of the treated animal or human.
摘要翻译： 一种通过抑制哺乳动物中β-葡糖醛酸糖苷酶的活性来减少内源和环境衍生化合物的不适当水平的方法，其包括向哺乳动物施用有效量的不溶于水的或微溶的持续的 公开了葡萄糖内酯或其类似物的释放前体。 葡萄糖内酯化合物的持续释放前体选自D-葡糖二酸，D-半乳糖酸，L-赖氨酸或其衍生物或类似物。 提供了可口服给药的葡萄糖内酯化合物的缓释前体，其形式为胶囊片剂，使得葡萄内酯酮或其类似物在经处理的动物或人的胃中缓慢释放。
-
公开(公告)号：US4937185A
公开(公告)日：1990-06-26
申请号：US79870
申请日：1987-07-31
IPC分类号： C07K14/47 , C12Q1/68 , G01N33/564 , G01N33/574
CPC分类号： G01N33/564 , C07K14/47 , C12Q1/6886 , G01N33/57476 , Y10S436/813 , Y10S436/825
摘要： A method and kit are described for detecting the presence of cancers and pre-neoplastic cells that produce an oncofetal phosphoprotein having a molecular weight of approximately 60,000 and having the capacity to increase the release of ribonucleic acid from cell nuclei. The method involves detecting the presence of auto-antibodies to this oncofetal phosphoprotein in a subject suspected of suffering from a cancer or pre-neoplastic cells which produce this cancer marker protein. The kit includes purified oncofetal phosphoprotein.
摘要翻译： 描述了一种方法和试剂盒，用于检测产生分子量约为60,000并具有增加核糖核酸从细胞核中释放的能力的癌症和前赘生物细胞的存在。 该方法涉及检测疑似患有癌症或产生该癌症标志物蛋白质的前赘生物细胞的受试者中该蛋白质磷蛋白的自身抗体的存在。 该试剂盒包括纯化的蛋白质磷蛋白。
-
3.发明授权
公开(公告)号：US4871661A
公开(公告)日：1989-10-03
申请号：US745924
申请日：1985-06-18
申请人： Thomas E. Webb , Dorothy E. Schumm , Margaret Hanausek-Walaszek , Zbigniew Walaszek , Raymond W. Lang
发明人： Thomas E. Webb , Dorothy E. Schumm , Margaret Hanausek-Walaszek , Zbigniew Walaszek , Raymond W. Lang
IPC分类号： C07K16/30
CPC分类号： C07K16/30 , Y10S530/806
摘要： Materials can be screened for carcinogenic properties by administering them to test animals and assaying biological tissue, preferably plasma, for the presence of a 60K cancer-associated phosphoprotein. The test is applicable to a wide range of chemically-diverse carcinogens and is not restricted to carcinogens having one particular mode of action.
摘要翻译： 可以通过施用它们来测试动物并测定生物组织，优选血浆，以存在60K癌症相关磷蛋白，筛选出致癌性质的材料。 该测试适用于各种各样的化学不同的致癌物质，并不限于具有一种特定作用模式的致癌物质。
-
4.发明授权
公开(公告)号：US5688505A
公开(公告)日：1997-11-18
申请号：US449336
申请日：1995-05-24
IPC分类号： G01N33/574 , A61K38/00 , A61K39/395 , A61P35/00 , C07K1/14 , C07K1/36 , C07K14/82 , C07K16/30 , C07K16/32 , C12N5/10 , C12N15/02 , C12P21/08 , C12R1/91 , C07K16/00 , C07K16/18
CPC分类号： C07K16/30 , C07K14/82 , A61K38/00 , C07K2317/73
摘要： The present invention provides a low cost, less toxic, anti-cancer immunotherapy which enhances the host's immune system ability to destroy or contain cancers, and also provides a diagnostic test for cancer. Specifically, the present invention provides monoclonal antibodies specific for, that is, specifically bind, oncofetal protein (OFP), a cancer cell product. Tumors treated with a single dose of the monoclonal antibodies against OFP are markedly reduced in size, and leukemic populations of cells treated with a single does of monoclonal antibodies against OFP are significantly decreased in number. Since the monoclonal antibodies of the present invention do not bind to tumor cells, the monoclonal antibody treatment overcomes the disadvantages associated with tumor cell targeting. Monoclonal antibodies to OFP offer a simple and inexpensive agent for use as a primary or adjuvant therapy against a wide variety of cancers and tumors in humans and other animals. The monoclonal antibodies against OFP are also employed to detect cancer in animal, including human patients.
摘要翻译： 本发明提供了低成本，毒性较小的抗癌免疫疗法，其增强了宿主的免疫系统破坏或容纳癌症的能力，并且还提供了癌症的诊断试验。 具体地说，本发明提供了特异性，特异性结合成骨蛋白（OFP），癌细胞产物的单克隆抗体。 用单剂量的针对OFP的单克隆抗体治疗的肿瘤的大小显着降低，并且使用单一针对OFP的单克隆抗体处理的细胞的白血病群体的数量显着减少。 由于本发明的单克隆抗体不与肿瘤细胞结合，所以单克隆抗体治疗克服了与肿瘤细胞靶向相关的缺点。 OFP的单克隆抗体提供了一种简单而廉价的药物，可用作针对人类和其他动物中各种癌症和肿瘤的主要或辅助治疗。 针对OFP的单克隆抗体也用于检测动物，包括人类患者中的癌症。
-
公开(公告)号：US5010107A
公开(公告)日：1991-04-23
申请号：US435543
申请日：1989-11-13
IPC分类号： A61K31/19
CPC分类号： A61K31/19
摘要： The present invention describes a protocol for achieving a very high degree of anticarcinogenic (or chemopreventive or cancer preventative) activity through the combination of a low suboptimal dose of a D-glucarolactone-based dietary anticarcinogen (i.e., calcium glucarate or CGT) with a low suboptimal dose of retinoid-based anticarcinogen (4-hydroxyphenyl retinamide or HPR). Since synergism is obtained by this combination, these two anticarcinogens can be employed at dosages far below toxic levels and at dosages that are practical as a food supplement.
摘要翻译： 本发明描述了通过将低次最低剂量的基于D-葡萄糖内酯的饮食抗癌药（即，葡萄糖酸钙或CGT）与低浓度的低葡萄糖酸（例如葡萄糖酸钙或CGT）的组合来实现非常高程度的致癌（或化学预防或癌症预防）活性的方案 次要剂量的类视黄醇类抗癌药（4-羟基苯基视黄酰胺或HPR）。 由于通过这种组合获得了协同作用，所以这两种抗癌剂可以以低于毒性水平的剂量和作为食品补充剂实用的剂量使用。
-
6.发明授权Method and composition for achieving cancer chemopreventive and chemotherapeutic activity 失效用于实现癌症化学预防和化学治疗活性的方法和组合物
公开(公告)号：US4997852A
公开(公告)日：1991-03-05
申请号：US436049
申请日：1989-11-13
IPC分类号： A61K31/19
CPC分类号： A61K31/19
摘要： The present invention describes a protocol for achieving a very high degree of anticarcinogenic (chemopreventive and chemotherapeutic) activity through the combination of low suboptimal doses of a D-glucarolactone-based dietary anticarcinogen with low suboptimal doses of a retinoid-based anticarcinogen. Synergism is obtained by this combination and these two anticarcinogens can be employed at dosages far below toxic levels and at dosages that are practical as a food supplement.
摘要翻译： 本发明描述了通过低次要剂量的基于D-葡萄糖内酯的膳食抗癌药与低次优剂量的基于类视黄醇的抗癌药物的组合来实现非常高程度的致癌（化学预防和化学治疗）活性的方案。 通过这种组合获得协同作用，并且这两种抗癌剂可以以低于毒性水平的剂量和作为食物补充剂实用的剂量使用。
-
公开(公告)号：US5650300A
公开(公告)日：1997-07-22
申请号：US452252
申请日：1995-05-26
IPC分类号： G01N33/574 , A61K38/00 , A61K39/395 , A61P35/00 , C07K1/14 , C07K1/36 , C07K14/82 , C07K16/30 , C07K16/32 , C12N5/10 , C12N15/02 , C12P21/08 , C12R1/91 , C07K16/18 , C12N5/12
CPC分类号： C07K16/30 , C07K14/82 , A61K38/00 , C07K2317/73
摘要： The present invention provides a low cost, less toxic, anti-cancer immunotherapy which enhances the host's immune system ability to destroy or contain cancers, and also provides a diagnostic test for cancer. Specifically, the present invention provides monoclonal antibodies specific for, that is, specifically bind, oncofetal protein (OFP), a cancer cell product. Tumors treated with a single dose of the monoclonal antibodies against OFP are markedly reduced in size, and leukemic populations of cells treated with a single does of monoclonal antibodies against OFP are significantly decreased in number. Since the monoclonal antibodies of the present invention do not bind to tumor cells, the monoclonal antibody treatment overcomes the disadvantages associated with tumor cell targeting. Monoclonal antibodies to OFP offer a simple and inexpensive agent for use as a primary or adjuvant therapy against a wide variety of cancers and tumors in humans and other animals. The monoclonal antibodies against OFP are also employed to detect cancer in animal, including human patients.
摘要翻译： 本发明提供了低成本，毒性较小的抗癌免疫疗法，其增强了宿主的免疫系统破坏或容纳癌症的能力，并且还提供了癌症的诊断试验。 具体地说，本发明提供了特异性，特异性结合成骨蛋白（OFP），癌细胞产物的单克隆抗体。 用单剂量的针对OFP的单克隆抗体治疗的肿瘤的大小显着降低，并且使用单一针对OFP的单克隆抗体处理的细胞的白血病群体的数量显着减少。 由于本发明的单克隆抗体不与肿瘤细胞结合，所以单克隆抗体治疗克服了与肿瘤细胞靶向相关的缺点。 OFP的单克隆抗体提供了一种简单而廉价的药物，可用作针对人类和其他动物中各种癌症和肿瘤的主要或辅助治疗。 针对OFP的单克隆抗体也用于检测动物，包括人类患者中的癌症。
-
8.发明授权
公开(公告)号：US5532159A
公开(公告)日：1996-07-02
申请号：US222201
申请日：1994-04-01
IPC分类号： G01N33/574 , A61K38/00 , A61K39/395 , A61P35/00 , C07K1/14 , C07K1/36 , C07K14/82 , C07K16/30 , C07K16/32 , C12N5/10 , C12N15/02 , C12P21/08 , C12R1/91 , C12N5/12 , C07K16/18
CPC分类号： C07K16/30 , C07K14/82 , A61K38/00 , C07K2317/73
摘要： The present invention provides a low cost, less toxic, anti-cancer immunotherapy which enhances the host's immune system ability to destroy or contain cancers, and also provides a diagnostic test for cancer. Specifically, the present invention provides monoclonal antibodies specific for, that is, specifically bind, oncofetal protein (OFP), a cancer cell product. Tumors treated with a single dose of the monoclonal antibodies against OFP are markedly reduced in size, and leukemic populations of cells treated with a single does of monoclonal antibodies against OFP are significantly decreased in number. Since the monoclonal antibodies of the present invention do not bind to tumor cells, the monoclonal antibody treatment overcomes the disadvantages associated with tumor cell targeting. Monoclonal antibodies to OFP offer a simple and inexpensive agent for use as a primary or adjuvant therapy against a wide variety of cancers and tumors in humans and other animals. The monoclonal antibodies against OFP are also employed to detect cancer in animal, including human patients.
摘要翻译： 本发明提供了低成本，毒性较小的抗癌免疫疗法，其增强了宿主的免疫系统破坏或容纳癌症的能力，并且还提供了癌症的诊断试验。 具体地说，本发明提供了特异性，特异性结合成骨蛋白（OFP），癌细胞产物的单克隆抗体。 用单剂量的针对OFP的单克隆抗体治疗的肿瘤的大小显着降低，并且使用单一针对OFP的单克隆抗体处理的细胞的白血病群体的数量显着减少。 由于本发明的单克隆抗体不与肿瘤细胞结合，所以单克隆抗体治疗克服了与肿瘤细胞靶向相关的缺点。 OFP的单克隆抗体提供了一种简单而廉价的药物，可用作针对人类和其他动物中各种癌症和肿瘤的主要或辅助治疗。 针对OFP的单克隆抗体也用于检测动物，包括人类患者中的癌症。
-
公开(公告)号：USD310451S
公开(公告)日：1990-09-11
申请号：US37454
申请日：1987-04-13
申请人： Thomas E. Webb
设计人： Thomas E. Webb
-
公开(公告)号：US07571841B2
公开(公告)日：2009-08-11
申请号：US12015227
申请日：2008-01-16
CPC分类号： B25C1/08 , B65D83/207 , B65D83/24 , B65D83/54
摘要： An adapter configured for use in combination with a cap on a fuel cell having a closure formation, the cap having at least one leg portion and a corresponding foot extending from the leg, including a ring portion configured for engagement upon the closure formation of the fuel cell and including a top edge, a bottom edge, and a sidewall therebetween having an inner sidewall and an outer sidewall, a grooved portion defined by the inner sidewall, a convex gripping formation on the outer sidewall complementary to the closure formation, and at least one recessed formation adjacent the grooved portion for receiving the foot.
摘要翻译： 一种被配置为与具有封闭形成的燃料电池上的盖组合使用的适配器，所述盖具有至少一个支脚部分和从所述腿部延伸的对应脚部，所述脚部构造成用于在所述燃料的闭合形成时接合 并且包括顶部边缘，底部边缘和其间具有内侧壁和外侧壁的侧壁，由内侧壁限定的开槽部分，与封闭结构互补的外侧壁上的凸形夹持结构，并且至少 邻近凹槽部分的一个凹陷部分用于接收脚部。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.024 秒)
